NuCana PLC
NCNA0.660USD
0.000
收盤 04/24, 16:00（美東）報價延遲15分鐘
3.75M總市值
虧損本益比TTM
關於 NuCana PLC 公司
NuCana plc 是一家位於英國的臨牀階段生物製藥公司。該公司專注於通過應用其 ProTide 技術爲癌症患者開發治療效果。該公司的產品線包括 NUC-3373 和 NUC-7738。NUC-3373 是 5-氟尿嘧啶 (5-FU) 活性抗癌代謝物的 ProTide 轉化。5-FU 是一種處方抗癌劑。NUC-3373 已在針對晚期實體瘤患者的 I 期臨牀試驗中進行了評估，並且正在針對晚期結直腸癌患者進行 Ib/II 期臨牀試驗。NUC-7738 是核苷類似物 3'-脫氧腺苷 (3'-Da) 的 ProTide 轉化。該公司正在針對晚期實體瘤患者的 I/II 期臨牀試驗中評估 NUC-7738。其產品線還包括 Acelari，它是核苷類似物吉西他濱的 ProTide 轉化。該公司的子公司包括 NuCana, Inc.、NuCana Limited 和 NuCana BioMed Trustee Company Limited。
公司簡介
公司代碼NCNA
公司名稱NuCana PLC
上市日期Sep 28, 2017
成立日期1997
CEOMr. Hugh S. Griffith
員工數量20
證券類型Depository Receipt
年結日Sep 28
公司地址Lochside House
城市EDINBURGH
上市交易所NASDAQ Capital Market Consolidated
國家United Kingdom
郵編EH12 9DT
電話4401313571111
網址https://www.nucana.com/
公司代碼NCNA
上市日期Sep 28, 2017
成立日期1997
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Donald (Don) Munoz
Mr. Donald (Don) Munoz
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 3月22日 週六
更新時間: 3月22日 週六
持股股東
股東類型
持股股東
股東統計
佔比
Sofinnova Investments, Inc
3.51%
Abingworth Management Limited
2.35%
Susquehanna International Group, LLP
0.82%
Schonfeld Strategic Advisors LLC
0.79%
Acadian Asset Management LLC
0.75%
Other
91.78%
持股股東
股東統計
佔比
Sofinnova Investments, Inc
3.51%
Abingworth Management Limited
2.35%
Susquehanna International Group, LLP
0.82%
Schonfeld Strategic Advisors LLC
0.79%
Acadian Asset Management LLC
0.75%
Other
91.78%
股東類型
股東統計
佔比
Venture Capital
5.86%
Investment Advisor
2.08%
Hedge Fund
1.60%
Research Firm
1.12%
Investment Advisor/Hedge Fund
0.78%
Individual Investor
0.22%
Other
88.33%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
50
678.81K
11.95%
+387.28K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
2023Q1
81
667.89K
31.87%
-504.63K
2022Q4
87
672.60K
32.11%
-559.71K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Sofinnova Investments, Inc
199.52K
3.51%
+199.52K
--
Feb 14, 2025
Abingworth Management Limited
133.33K
2.35%
--
--
Dec 31, 2024
Susquehanna International Group, LLP
46.72K
0.82%
+46.72K
--
Dec 31, 2024
Schonfeld Strategic Advisors LLC
45.07K
0.79%
+45.07K
--
Dec 31, 2024
Acadian Asset Management LLC
42.41K
0.75%
+18.79K
+79.54%
Dec 31, 2024
Virtu Americas LLC
40.40K
0.71%
+40.40K
--
Dec 31, 2024
Baillie Gifford & Co.
36.70K
0.65%
--
--
Dec 31, 2024
Citadel Advisors LLC
25.00K
0.44%
+25.00K
--
Dec 31, 2024
Two Sigma Investments, LP
20.99K
0.37%
+20.99K
--
Dec 31, 2024
Glass Jacobson Wealth Advisors
15.00K
0.26%
--
--
Dec 31, 2024
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
公告日期
類型
比率
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1